Novo Nordisk to slash prices of weightloss drugs in US / Photo: © GETTY IMAGES NORTH AMERICA/AFP/File
-
Alan Greenspan: longtime Fed chief with a divided legacy
-
Leinster boss Cullen to step down at end of next season
-
'Has-been' Belgium stars scorched after Iran World Cup draw
-
Oil falls on US-Iran progress; pound holds up as Starmer resigns
-
Starmer resigns as UK PM, Burnham favourite to take over
-
France, Germany reach deal on arms maker KNDS, paving way for IPO
-
Latest developments on Europe's heatwave
-
France set for hottest day yet of heatwave
-
Keir Starmer: downfall of UK's unpopular PM
-
Gaza's surfers seek solace in the sea
-
MEXC Lists Arcium (ARX) with 70,000 USDT in Airdrop+ Rewards
-
EasyJet rejects £5 bn takeover offer from US equity firm
-
Europe scorched by latest heatwave
-
Mediators hail 'progress' in US-Iran talks after lengthy opening session
-
UK's Starmer resigns as prime minister
-
Coffee break: Starbucks Korea stores pause for training after 'Tank Day' fiasco
-
Rightist leaders congratulate Colombian president-elect
-
Rare Philippine school shooting kills three teens, wounds seven
-
Kenya labour minister accused over Russian forced recruitment
-
Crude prices drop after 'positive' US-Iran talks
-
Some France schools closed for day of searing heat
-
Tuchel's England face defensive questions despite flying start at World Cup
-
Frankfurt to All Blacks: New Zealand pick first German-born player
-
Not just a hideout: Sahel forests provide base for jihadists
-
Ageless Messi has World Cup scoring record in his sights
-
Africa faces child surgery crisis as key anaesthesia runs out
-
Trump-backed populist wins razor-tight Colombia vote, sparking protests
-
J-Bay: S.Africa's surf mecca missing out on the global tour
-
'Progress', say mediators, after Iran-US talks towards ending war
-
Key points from the first round of Iran-US talks
-
European countries close schools, cancel trains as heatwave set to intensify
-
Crude prices drop, most stocks rise on 'positive' US-Iran talks
-
'Progress', say mediators, after Iran-US talks on ending war
-
Slimy beans: Japanese natto disgusts and delights the world
-
Clark wins despite hecklers but hopes not to be 'heel of the PGA'
-
Cape Verde targeting World Cup knockout rounds after Uruguay draw: coach
-
Father's Day near-miss at US Open brings Burns to tears
-
New coach Rennie names Savea as All Blacks captain
-
Scheffler praises Clark's resolve in gutsy US Open triumph
-
Yamal kickstarts Spain World Cup bid as Cape Verde stun Uruguay
-
Cape Verde fight back for second World Cup draw against Uruguay
-
Mexican fans rally behind Iran as 'our second team' at World Cup
-
Iran-US talks to continue through the night
-
Trump-backed candidate wins razor-tight Colombia presidential election
-
Clark edges Burns by one stroke for second US Open title
-
Iran coach hails 'great achievement' after second World Cup draw
-
Curacao firmly on the map after World Cup heroics
-
Pro-Trump presidential hopeful takes early lead as Colombia counts votes
-
Trump say repairs to begin 'immediately' for Washington pool renovation
-
Yamal off the mark at World Cup in Spain rout as Iran hold Belgium
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
L.Maurer--VB